✦ LIBER ✦

A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

✍ Scribed by Glenwood Goss; Frances A. Shepherd; Scott Laurie; Isabelle Gauthier; N. Leighl; Eric Chen; Ronald Feld; Jean Powers; Lesley Seymour

Book ID: 116429857
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 137 KB
Volume: 45
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2008.10.022

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

93 POSTER Phase I study of daily oral AZ

93 POSTER Phase I study of daily oral AZD2171, an inhibitor of the vascular endothelial growth factor receptors (VEGFR), in combination with oxaliplatin and Infusional 5-Fu (mFOLFOX6) in patients with advanced colorectal cancer (CRC): a study of the National Cancer Institute of Canada Clinical Trials Group

✍ E. Chen; D. Jonker; M. Maclean; J. Wells; S. Mathews; J. Robertson; L. Seymour 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB

VP-16 and carboplatin in previously untr

VP-16 and carboplatin in previously untreated patients with extensive small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group

✍ Evans, WK; Eisenhauer, E; Hughes, P; Maroun, JA; Ayoub, J; Shepherd, FA; Feld, R 📂 Article 📅 1988 🏛 Nature Publishing Group 🌐 English ⚖ 991 KB

A phase I study of the oral vascular end

A phase I study of the oral vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor PTK787/ZK 222584 on a twice daily schedule in patients with advanced cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Phase I/II and Pharmacokinetic Study of

Phase I/II and Pharmacokinetic Study of Intravenous Vinflunine in Combination With Cisplatin for the Treatment of Chemonaive Patients With Advanced Non–Small-Cell Lung Cancer

✍ Pierre-Jean Souquet; Maciej Krzakowski; Rodrig Ramlau; Xu-Shan Sun; Guillermo Lo 📂 Article 📅 2010 🏛 CIG Media Group, LP. 🌐 English ⚖ 484 KB

Phase II study of pemetrexed disodium, a

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma : A study of the national cancer institute of Canada clinical trials group

✍ Frances A. Shepherd; Janet Dancey; Andrew Arnold; Alan Neville; James Rusthoven; 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Background: Pemetrexed disodium (alimta [eli lilly and company, indianapolis, in], ly231514, multitargeted antifolate) is a new multitargeted antifolate agent that inhibits multiple enzymes in the folate pathway. phase ii trials showed single-agent response rates of 16% and 23% in untreated pati

92 POSTER Effects of AZD2171 on pharmaco

92 POSTER Effects of AZD2171 on pharmacokinetics (PK) of carboplatin (C) and paclitaxel (P) in patients with advanced non-small cell lung cancer (NSCLC): a study of the National Cancer Institute of Canada Clinical Trials Group

✍ E. Chen; W. Zhang; S. Lauri; A. Arnold; I. Gauthier; G. Goss; P. Ellis; F. Sheph 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 57 KB